Autolus Therapeutics Plc (AUTL)
2.24
-0.07
(-3.03%)
USD |
NASDAQ |
Sep 02, 16:00
2.23
-0.01
(-0.45%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (Annual) : 128.59M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 128.59M |
| December 31, 2024 | 118.79M |
| December 31, 2023 | 149.98M |
| December 31, 2022 | 141.87M |
| December 31, 2021 | 134.70M |
| Date | Value |
|---|---|
| December 31, 2020 | 134.80M |
| December 31, 2019 | 105.42M |
| September 30, 2018 | 36.15M |
| September 30, 2017 | 16.01M |
| September 30, 2016 | 10.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Bicycle Therapeutics Plc | 275.85M |
| Biodexa Pharmaceuticals Plc | 5.026M |
| argenx SE | 1.356B |
| NuCana Plc | 16.79M |
| Mereo BioPharma Group Plc | 17.81M |